Curevac presents preliminary data from phase 1 study expansion of oncology candidate cv8102

Data confirm cv8102's safety and ability to strongly mobilize the immune system against tumors final data of complete phase 1 dose-escalation and expansion study expected in h1 2023 tÜbingen, germany and boston, ma / accesswire / november 11, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced data from the phase 1 expansion study of cv8102, the company's non-coding rna candidate in oncology.
CVAC Ratings Summary
CVAC Quant Ranking